SecBot SecBot

BIAF

bioAffinity Technologies, Inc.
Nasdaq· Services-Commercial Physical & Biological Research· Inc. DE· CIK 0001712762 Biotech & Drug Discovery
$2.83 +0.03 (+1.07%)
Oct 26 4:00 PM ET · prev $2.80
Market cap
$4.1M
Nano cap
Next earnings
Nov 12
in 16 days
1 year
−92.7%
from $38.85 · Oct 27
30 days
−61.8%
from $7.41
52-week range
$2.80–71.10
−96% from high · low Oct 23
Avg volume 20D
1.96M
Oct 8 spike 35.25M
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
28
analyzed by SecBot
SecBot read MIXED 18 reports · 90 days
Balance 4 bearish · 4 bullish · 1 mixed · 9 neutral oldest → newest, height = score
Avg score ·High conf. 14/18 ·Next Earnings date, Nov 12, 2026
Strongest BEARISH bioAffinity Technologies is raising approximately $4M in net proceeds through a registered direct offering…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 1 trimmed or exited.

  • TrendDOWNTREND

    56% below its 50-day average. New closing low $2.80 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
STATE STREET CORPADD24,086$19.6K
NORTHERN TRUST CORPADD16,748$13.6K
UBS Group AGTRIM4,204$3.4K
GEODE CAPITAL MANAGEMENT, LLCADD48,293$185.0K
CITIGROUP INCNEAR_EXIT57$218.00
CITIGROUP INCDOUBLED7,741$9.1K
BANK OF AMERICA CORP /DE/NEAR_EXIT38$45.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Apr 2025
Recent actions
DateFirmActionRating
Apr 1, 2025Maxim Group
DOWNGRADE
DOWNGRADEHold
Jul 23, 2024Maxim Group
INITIATE
INITIATEBuy

Earnings setup

Estimates
Nov 12
reports in 16 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
BIAF Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Sep 17, 2026
Trading halt
Halt Resumed: BIAF — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-17T16:26:12.000Z | Resumed 2026-09-17T16:31:12.000Z
Sep 17, 2026
Trading halt
Trading Halt: BIAF — LUDP (Volatility Trading Pause)
bioAffinity Technologies, Cm | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Sep 17, 2026
Reg SHO list
Reg SHO Threshold: BIAF exited the threshold list
BIOAFFINITY TECHNOLOGIES INC C | On list since 2026-09-09
Sep 8, 2026
Listing
Listing Status: BIAF — Normal (was Deficient)
bioAffinity Technologies, Inc. - Common Stock | Nasdaq Financial Status Indicator D → N
Sep 9, 2026
Reg SHO list
Reg SHO Threshold: BIAF entered the threshold list
BIOAFFINITY TECHNOLOGIES INC C | 5+ consecutive settlement days of fails-to-deliver ≥10k shares and ≥0.5% of shares outstanding

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Sep 17, 2026Volatility PauseResumed
Sep 4, 2026Volatility PauseResumed
Sep 1, 2026Volatility PauseResumed
Aug 21, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 SEC
bioAffinity Technologies is holding a special meeting on November 20, 2026, to seek stockholder approval for the…
DEF 14A — Impact 5/10
Oct 15, 2026 SEC
bioAffinity Technologies filed an 8-K announcing a Learning Theater presentation at CHEST 2026 on October 21, 2026…
8-K — Impact 3/10
Oct 13, 2026 SEC
bioAffinity Technologies filed an 8-K announcing a poster presentation at CHEST 2026 on its investigational…
8-K — Impact 3/10
Sep 17, 2026 Trading halt
Halt Resumed: BIAF — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-17T16:26:12.000Z | Resumed 2026-09-17T16:31:12.000Z
Jun 30, 2026 Inst.
STATE STREET CORP — ADD
24,086 shares ($19.6K)
Jun 30, 2026 Inst.
NORTHERN TRUST CORP — ADD
16,748 shares ($13.6K)

SecBot reports

28 filings · 6 bullish · 7 bearish · 1 mixed · 14 neutral
All BIAF filing & press-release reports (28)